213 related articles for article (PubMed ID: 31087772)
1. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.
Lai Q; Vitale A; Iesari S; Finkenstedt A; Mennini G; Onali S; Hoppe-Lotichius M; Manzia TM; Nicolini D; Avolio AW; Mrzljak A; Kocman B; Agnes S; Vivarelli M; Tisone G; Otto G; Tsochatzis E; Rossi M; Viveiros A; Ciccarelli O; Cillo U; Lerut J;
Liver Transpl; 2019 Jul; 25(7):1023-1033. PubMed ID: 31087772
[TBL] [Abstract][Full Text] [Related]
2. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
4. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
5. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
7. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
8. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
9. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
12. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
13. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
[TBL] [Abstract][Full Text] [Related]
14. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
[TBL] [Abstract][Full Text] [Related]
15. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
[TBL] [Abstract][Full Text] [Related]
16. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
17. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
[TBL] [Abstract][Full Text] [Related]
18. Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation.
Xing M; Kim HS
Cancer Med; 2017 Jan; 6(1):26-35. PubMed ID: 27860456
[TBL] [Abstract][Full Text] [Related]
19. Bridging to liver transplantation in HCC patients.
Kollmann D; Selzner N; Selzner M
Langenbecks Arch Surg; 2017 Sep; 402(6):863-871. PubMed ID: 28755240
[TBL] [Abstract][Full Text] [Related]
20. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
